Boehringer Ingelheim & Taking Cancer On

Cancer

We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations.

Latest Article

Illustration of a patient receiving help for a healthcare professional

The power of patient advocacy in cancer care

Learn more about patient Larry and UICC president Jeff Dunn's commitment to patient empowerment.

Brightline-1 trial launch in rare sarcoma

Find out more from Mehdi Lahmar, Clinical Program Leader for Oncology, about our commitment to patients with Dedifferentiated Liposarcoma (DDLPS).

Two hands shaping some medication into a heart

Cancer

Why cancer care is personal for us

Find out more about Boehringer Ingelheim’s generational commitment to transforming cancer care.

Cancer

Taking Cancer On: The Podcast

From early stage discovery to clinical trials and approval, we’re Taking Cancer On. Click here to access the podcast homepage, where you will find all the available episodes.

Cancer

Win Fight Against Cancer

At Boehringer Ingelheim, we believe this can be the generation that redefines many cancers as curable diseases. We want to be part of this transformation.

Collaborations

Boehringer Ingelheim is involved in long-term collaborations with world leading academics, industry, regulators and payors, as well as patients and advocacy organizations.
We take a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful areas of cancer research.